PMID- 25918454 OWN - NLM STAT- MEDLINE DCOM- 20151224 LR - 20181113 IS - 1875-8630 (Electronic) IS - 0278-0240 (Print) IS - 0278-0240 (Linking) VI - 2015 DP - 2015 TI - Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide. PG - 780743 LID - 10.1155/2015/780743 [doi] LID - 780743 AB - BACKGROUND: Brain-derived neurotrophic factor (BDNF) is associated with sympathetic activation. However, the effects of BDNF on diabetic nephropathy are unknown. The aim of this study was to assess the estimated glomerular filtration rates (eGFRs) and changes in serum BDNF levels in type 2 diabetic subjects treated with antihypertensive medications. METHODS: In this randomized, double-blind clinical trial, type 2 diabetic subjects with hypertension were assigned to either the benazepril/amlodipine or valsartan/hydrochlorothiazide treatment groups for a 16-week period. The post hoc analyses were based on increased or decreased serum BDNF levels. RESULTS: Of the 153 enrolled subjects, the changes in eGFR were significantly and inversely correlated with those in BDNF in the 76 subjects treated with valsartan/hydrochlorothiazide (r = -0.264, P = 0.021) but not in the 77 subjects treated with benazepril/amlodipine (r = -0.025, P = 0.862). The 45 subjects with increased BDNF following valsartan/hydrochlorothiazide treatment exhibited a significantly reduced eGFR (-8.8 +/- 14.9 mL/min/1.73 m(2); P < 0.001). Multivariate regression analysis revealed that increased serum BDNF represents an independent factor for reduced eGFR (95% confidence interval between -0.887 and -0.076, P = 0.020). CONCLUSIONS: Increased serum BDNF is associated with reduced eGFR in type 2 diabetic subjects treated with valsartan/hydrochlorothiazide but not with amlodipine/benazepril. FAU - Lee, I-Te AU - Lee IT AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan ; School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan ; School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan. FAU - Sheu, Wayne Huey-Herng AU - Sheu WH AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan ; School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan ; School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan. FAU - Hung, Yi-Jen AU - Hung YJ AUID- ORCID: 0000-0001-5318-9001 AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan. FAU - Chen, Jung-Fu AU - Chen JF AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan. FAU - Wang, Chih-Yuan AU - Wang CY AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei 10617, Taiwan. FAU - Lee, Wen-Jane AU - Lee WJ AD - Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20150330 PL - United States TA - Dis Markers JT - Disease markers JID - 8604127 RN - 0 (Antihypertensive Agents) RN - 0 (Benzazepines) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0J48LPH2TH (Hydrochlorothiazide) RN - 1J444QC288 (Amlodipine) RN - 80M03YXJ7I (Valsartan) RN - UDM7Q7QWP8 (benazepril) SB - IM MH - Aged MH - Amlodipine/adverse effects MH - Antihypertensive Agents/*adverse effects MH - Benzazepines/adverse effects MH - Brain-Derived Neurotrophic Factor/*blood MH - Diabetes Mellitus, Type 2/*blood/drug therapy MH - Diabetic Nephropathies/*blood/chemically induced MH - Female MH - *Glomerular Filtration Rate MH - Humans MH - Hydrochlorothiazide/adverse effects MH - Male MH - Middle Aged MH - Valsartan/adverse effects PMC - PMC4397057 EDAT- 2015/04/29 06:00 MHDA- 2015/12/25 06:00 PMCR- 2015/03/30 CRDT- 2015/04/29 06:00 PHST- 2014/09/23 00:00 [received] PHST- 2015/03/17 00:00 [revised] PHST- 2015/03/18 00:00 [accepted] PHST- 2015/04/29 06:00 [entrez] PHST- 2015/04/29 06:00 [pubmed] PHST- 2015/12/25 06:00 [medline] PHST- 2015/03/30 00:00 [pmc-release] AID - 10.1155/2015/780743 [doi] PST - ppublish SO - Dis Markers. 2015;2015:780743. doi: 10.1155/2015/780743. Epub 2015 Mar 30.